LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Home・Aandelen Lijst・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

43.78 1.37

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

43.64

Max

44.36

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.2M -91M
Winstmarge	-867.293
Werknemers	316
EBITDA	4M -90M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+27.13% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	139M 3.4B
Vorige openingsprijs	42.41
Vorige sluitingsprijs	43.78

Nieuwssentiment

By Acuity

50%

165 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.81 / 38.24 Steun & Weerstand

Xenon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 dec 2025, 17:29 UTC

Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 dec 2025, 16:47 UTC

Belangrijke Marktbewegers

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 dec 2025, 16:10 UTC

Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19 dec 2025, 22:33 UTC

Winsten

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 dec 2025, 22:19 UTC

Winsten

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 dec 2025, 21:48 UTC

Acquisities, Fusies, Overnames

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dec 2025, 21:44 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 dec 2025, 21:38 UTC

Winsten

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 dec 2025, 21:00 UTC

Marktinformatie

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 dec 2025, 20:23 UTC

Marktinformatie

Oil Futures End Down Week on Up Note -- Market Talk

19 dec 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 dec 2025, 18:38 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 dec 2025, 18:00 UTC

Marktinformatie

Winsten

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 dec 2025, 17:41 UTC

Winsten

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 dec 2025, 17:24 UTC

Marktinformatie

Winsten

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 dec 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

19 dec 2025, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

19 dec 2025, 16:29 UTC

Winsten

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 dec 2025, 16:20 UTC

Acquisities, Fusies, Overnames

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 dec 2025, 16:19 UTC

Acquisities, Fusies, Overnames

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 dec 2025, 16:18 UTC

Acquisities, Fusies, Overnames

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 dec 2025, 16:16 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

19 dec 2025, 16:16 UTC

Marktinformatie

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 dec 2025, 16:05 UTC

Acquisities, Fusies, Overnames

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dec 2025, 16:04 UTC

Acquisities, Fusies, Overnames

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dec 2025, 15:37 UTC

Marktinformatie

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19 dec 2025, 15:21 UTC

Marktinformatie

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19 dec 2025, 15:09 UTC

Marktinformatie

Gold Flat But Set for Weekly Gains -- Market Talk

19 dec 2025, 15:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

19 dec 2025, 15:09 UTC

Winsten

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Peer Vergelijking

Prijswijziging

Xenon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

27.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 54.96 USD 27.13%

Hoogste 65 USD

Laagste 44 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Xenon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan Xenon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.81 / 38.24Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

165 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.